Opioid withdrawal is rarely fatal itself, but relapse after withdrawal carries extreme overdose risk. Tolerance drops within days of stopping, a previously "normal" dose can cause fatal overdose after even brief abstinence. If you or someone you know is stopping opioids, please contact a doctor, call SAMHSA at 1-800-662-4357, or go to an emergency room. Naloxone (Narcan) should be available. This is a medical situation.
Opioid withdrawal symptoms: anxiety, agitation, muscle cramps, sweating, goosebumps, runny nose, nausea, vomiting, diarrhea, and rapid heart rate. Short-acting opioids (heroin, oxycodone): onset 8–24 hours, peak 36–72 hours, resolve 5–7 days. Long-acting (methadone): onset 36–48 hours, peaks later, lasts 2–3 weeks. Withdrawal is not typically fatal, the deadly danger is relapse after abstinence, when tolerance has dropped and a previous dose causes overdose. Medication-assisted treatment (buprenorphine, methadone, naltrexone) reduces overdose mortality by 50%+ and is the evidence-based standard of care.
Intense restlessness, inability to get comfortable, psychological panic. Often the first and most distressing symptom.
Severe, flu-like muscle pain throughout the body. "Bone-deep" aching is a classic descriptor. Peak intensity at 36–72 hrs.
Profuse sweating alternating with chills and goosebumps ("cold turkey", the appearance of goose skin gave the term its name).
Lacrimation (tearing eyes) and rhinorrhea (runny nose) are autonomic symptoms of opioid withdrawal, controlled by the sympathetic nervous system.
Can be severe and lead to dangerous dehydration. Anti-nausea medications help significantly. IV fluids may be needed for severe cases.
Severe abdominal cramping and diarrhea, sometimes lasting days. Opioids slow GI motility, removal causes rebound hypermotility.
Severe sleep disruption, often the most persistent symptom. Can last weeks after acute withdrawal resolves.
Uncontrollable excessive yawning is a specific autonomic sign of opioid withdrawal, appearing early (6–12 hours into withdrawal).
Opioids constrict pupils (miosis). Withdrawal causes the opposite, dilated pupils (mydriasis) are a clinical sign of active withdrawal.
Tachycardia and hypertension reflect sympathetic nervous system activation. Usually manageable, rarely requires emergency intervention on its own.
Short-acting opioids (heroin, oxycodone, hydrocodone, morphine): first symptoms appear 8–24 hours after last dose. Long-acting opioids (methadone): slower onset at 36–48 hours. Yawning, runny nose, anxiety, and restlessness are typically first to appear.
The most intense phase. Muscle cramps, vomiting, diarrhea, sweating, and extreme agitation reach maximum intensity. This is the window of greatest relapse risk, the discomfort is severe enough that most people relapse without medical support or MAT. Dehydration risk is highest here.
Physical symptoms begin subsiding. Muscle aches ease. GI symptoms improve. Energy starts returning. Insomnia and anxiety persist longest. Short-acting opioid withdrawal largely resolves by day 7, methadone withdrawal can extend to 2–3 weeks.
After acute withdrawal resolves, many people experience PAWS: persistent anxiety, depression, sleep difficulty, cognitive fog, and drug cravings that can last months to over a year. PAWS is the primary driver of long-term relapse risk and is a key reason MAT, which manages PAWS symptoms pharmacologically, dramatically improves recovery outcomes.
COWS (Clinical Opiate Withdrawal Scale) is used by clinicians to assess withdrawal severity and time buprenorphine induction. Starting buprenorphine too early can precipitate severe precipitated withdrawal.
Buprenorphine induction typically begins when COWS score reaches 8–12 (early moderate withdrawal). A COWS score of 0–7 suggests too early for induction.
Opioid tolerance, the brain's adaptation to regular opioid exposure, drops rapidly during withdrawal. Within 3–5 days of stopping, someone's tolerance may have fallen to a fraction of what it was. A dose that was "normal" before withdrawal can now cause fatal respiratory depression.
This is the primary reason the post-withdrawal period carries the highest overdose mortality risk of any phase of opioid use. It explains the pattern seen in overdose statistics: people who have recently left incarceration, completed inpatient detox, or been briefly hospitalized are massively overrepresented in overdose deaths, because their tolerance dropped during the gap and they returned to prior doses.
Medication-assisted treatment, particularly buprenorphine and methadone, which maintain opioid receptor engagement at a managed level, is the single most effective intervention for preventing this outcome. Studies show MAT reduces opioid overdose mortality by 50% or more.
Partial opioid agonist. Reduces cravings and withdrawal without producing a strong high. Can be prescribed by office-based physicians. First-line treatment for OUD.
Long-acting full agonist. Highly effective for severe OUD. Dispensed through licensed clinics. Eliminates withdrawal while blocking illicit opioid effects.
Opioid antagonist, blocks opioid effects entirely. Monthly injection. Requires full detox first (no active opioids). Effective for motivated patients with support systems.
Anxiety, agitation, muscle cramps, sweating, goosebumps, runny nose, tearing eyes, yawning, nausea, vomiting, diarrhea, abdominal cramps, insomnia, elevated heart rate, and dilated pupils. Begin 8–24 hours after last dose (short-acting) or 36–48 hours (long-acting).
Short-acting: peaks at 36–72 hours, largely resolves in 5–7 days. Long-acting (methadone): peaks later, lasts 2–3 weeks. PAWS (anxiety, depression, cravings, insomnia) can persist for months to over a year.
The withdrawal itself is rarely fatal (unlike alcohol). The danger is dehydration from vomiting/diarrhea, and critically, relapse overdose risk. Tolerance drops rapidly during withdrawal, returning to a prior dose can be fatal. Medical supervision and naloxone availability are important.
Clinical Opiate Withdrawal Scale, an 11-item clinical assessment used to measure withdrawal severity and guide buprenorphine induction timing. Scores: 5–12 mild, 13–24 moderate, 25–36 moderately severe, 37+ severe.
Medication-assisted treatment uses buprenorphine (Suboxone), methadone, or naltrexone (Vivitrol) combined with counseling to treat opioid use disorder. MAT reduces overdose mortality by 50%+ and is the evidence-based standard of care per SAMHSA and ASAM.
Relapse after abstinence. Tolerance drops within days of stopping, a prior "normal" dose can cause fatal overdose after even brief abstinence. The post-detox period is the highest-risk window for overdose death.
Timeline varies by opioid type. Short-acting opioids (heroin, oxycodone): symptoms begin 8–24 hours after last use, peak at 36–72 hours, largely resolve in 4–10 days. Long-acting opioids (methadone): symptoms begin 36–48 hours after last use, peak at 72–96 hours, can last 2–3 weeks. Post-acute withdrawal syndrome (PAWS), mood, energy, sleep, and craving issues, can persist 6–18 months.
People consistently describe opioid withdrawal as the worst flu of their life, significantly amplified. Symptoms include: intense anxiety and restlessness ('jumping out of your skin'), severe muscle aches and cramping, insomnia despite exhaustion, hot and cold flashes with goosebumps, nausea, vomiting, diarrhea, abdominal cramping, runny nose and eyes, excessive yawning, and an overwhelming craving for opioids. The psychological distress often exceeds the physical.
Unlike alcohol withdrawal, opioid withdrawal is rarely directly fatal in otherwise healthy adults. However, dangerous complications can occur: severe dehydration from vomiting and diarrhea (can lead to electrolyte imbalances and cardiac events), aspiration of vomit during sleep, extreme psychiatric distress leading to suicidal behavior, and extremely high overdose risk if the person uses opioids after a period of abstinence (tolerance resets). Medical supervision is strongly recommended.
Buprenorphine (Suboxone) is the gold standard. It significantly reduces withdrawal symptoms and cravings and transitions directly to maintenance treatment. Methadone (in licensed clinics) achieves similar results. Clonidine (non-opioid) reduces the autonomic symptoms (sweating, nausea, anxiety). Loperamide for diarrhea, NSAIDs for muscle pain, and antiemetics for nausea are supportive. Buprenorphine-assisted withdrawal produces significantly better long-term outcomes than 'detox only.'
Rapid opioid detoxification involves placing a patient under general anesthesia and administering naloxone to precipitate withdrawal while unconscious. Research shows it carries significant risks (including fatalities) with no better long-term outcomes than standard medication-assisted treatment. Major medical organizations do not recommend rapid detox. It has largely been abandoned by mainstream addiction medicine.
Post-Acute Withdrawal Syndrome (PAWS) following opioid use disorder includes: persistent low mood and anhedonia (inability to feel pleasure), fatigue, poor concentration, sleep disruption, intermittent cravings, and dysphoria that can persist for 6–18 months. PAWS is the primary driver of relapse beyond the acute withdrawal period. MAT (buprenorphine or methadone) effectively prevents PAWS by maintaining opioid receptor signaling during the brain's healing process.
Opioid withdrawal is essentially a state of adrenergic hyperactivity, the nervous system rebound from opioid suppression. The brain's locus coeruleus (which regulates arousal and norepinephrine) becomes hyperactive, producing: elevated heart rate and blood pressure, sweating, dilated pupils, goosebumps, anxiety, restlessness, and pain sensitization. The GI system, which has significant opioid receptors, rebounds with diarrhea and cramping.
Direct fatality from uncomplicated opioid withdrawal in a healthy adult is rare. However, fatality risk is real from: severe dehydration and electrolyte imbalance (especially in people with cardiac conditions), suicide (opioid withdrawal is intensely dysphoric and suicidal ideation is common), aspiration of vomit, and, most commonly, overdose when someone who couldn't tolerate withdrawal uses opioids after a period of abstinence with reset tolerance. Medical supervision addresses all these risks.
Home management (only appropriate for mild cases): stay hydrated (water, sports drinks), OTC loperamide for diarrhea, OTC anti-nausea medication, ibuprofen or acetaminophen for muscle pain, heating pads for muscle cramps, and melatonin for sleep. Most importantly: have naloxone available in case of relapse during or after withdrawal. For moderate-severe withdrawal or if you've had complications before, medical management with buprenorphine or clonidine is significantly more comfortable and safer.
Buprenorphine (sold as Suboxone combined with naloxone) is a partial opioid agonist that binds opioid receptors strongly enough to prevent withdrawal and cravings without producing the full euphoria of full agonists. It dramatically reduces the physical discomfort of withdrawal when initiated correctly. It can be prescribed by certified physicians in office-based settings, dramatically expanding access compared to methadone clinics. Continued maintenance on buprenorphine significantly reduces relapse and overdose risk.
The psychological intensity of opioid withdrawal exceeds the physical for many people. Opioids artificially regulate emotions and dysphoria, the neurological 'floor' is raised while using. In withdrawal, that floor drops precipitously: anxiety, depression, inability to feel pleasure (anhedonia), hopelessness, and in many cases suicidal ideation emerge. This dysphoria is a powerful driver of relapse and a key reason why medical support during withdrawal is so important.
Appetite is severely reduced during acute withdrawal. Priorities: fluid replacement (diarrhea and sweating cause dehydration, electrolyte drinks like Pedialyte or sports drinks), small frequent bland meals (BRAT diet: banana, rice, applesauce, toast) when appetite permits, and avoiding large meals that can worsen nausea. Nutritional support improves as withdrawal progresses. Most people have substantially better appetite by day 5–7.
Research is clear: longer MAT duration produces better outcomes. SAMHSA guidelines recommend at least 1–2 years of MAT for moderate-severe OUD. Many people do well with indefinite maintenance. The risk of relapse and overdose is highest in the first year of abstinence. MAT decisions should be individualized and made with an addiction medicine provider based on recovery stability, life circumstances, and patient preference.
Signs of adequately managed withdrawal: symptoms are uncomfortable but tolerable, heart rate and blood pressure are within safe range, able to drink fluids without vomiting, walking and functioning despite discomfort, and not experiencing severe psychiatric symptoms requiring immediate intervention. The goal of medical opioid withdrawal management is not zero discomfort, it's safe, tolerable, and a foundation for ongoing treatment.
Forge tracks your streak, logs cravings, and marks every milestone as your body heals. Free to download.
Download Forge Free →Also from Forge
Forge Desktop blocks porn and gambling sites on your computer, and tells one person you choose if you turn the blocker off. $7/month, separate from the app.
It won't help with what this article is about. It blocks websites. It can't block a shop, a bar, or a dealer. Mentioned here only because people ask, and because it's the same account.
Look at Forge DesktopFor what you're reading about here, the Forge iPhone app is the right tool, streak tracking, an AI coach, and an SOS mode for when a craving peaks.
Forge Desktop is a separate product from the Forge iPhone app, with its own subscription. Paying for one doesn't include the other. If you already have Forge Pro on your phone, that stays exactly as it is.